BTK and B-cell chronic lymphocytic leukemia: Importantly, we show increased expression of miR-494, miR-495, and miR-543 and PTEN downregulation in response to BTK inhibition in therapy-relapsed patient-derived primary CLL cells vs those treatment-naïve.